Back to results
US 7,622,114 B2Granted
Assay methods for immediate diagnosis of cause of stroke
AssigneeCIS Biotech, Inc.
InventorSvetlana A. Dambinova
Life of this patent
Estimating the term…
Abstract
A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
Claims11
A method for aiding in the differential diagnosis of ischemic versus hemorrhagic stroke comprising:
- a) obtaining a test sample of blood, plasma or serum from a human subject at the time said subject is suspected of suffering from an ischemic or hemorrhagic stroke;
- b) analyzing the obtained test sample for the amount of (i) NR2A N-terminal domain fragment peptide having SEQ ID NO:
- 3 and NR2B N-terminal domain fragment peptide having SEQ ID NO:
- 12 (NR2A-B receptor peptides) or (ii) NR2 antibody that binds NR2A N-terminal domain fragment peptide having SEQ ID NO:
- 3;
- c) comparing the result of step (b) with a corresponding reference amount of said NR2A-B receptor peptides or NR2 antibody, or a combination thereof, wherein the corresponding reference amount is derived from a population of apparently healthy human subjects;
- and
- d) if the amount determined in step (b) exceeds the corresponding reference amount, diagnosing said human as having an increased probability of having an ischemic stroke over hemorrhagic stroke.
5 more elements
Dependencies are inferred from the claim text.